Plasminogen Activator Inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the chinese han population: A meta-analysis

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Li, Yan yan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHINESE; CORONARY ARTERY DISEASE; CORONARY RISK; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1 4G/5G GENE; SYSTEMATIC REVIEW; ASIAN; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; META ANALYSIS; RISK FACTOR;

PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84859317385     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033511     Document Type: Article

References (30)

1. Hamsten A, Wiman B, de Faire U, Blombäck M, (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557-1563.
2. Held C, Hjemdahl P, Rehnqvist N, Wallén NH, Forslund L, et al. (1997) Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. J Intern Med 241: 59-69.
3. Eriksson P, Kallin B, van't Hooft FM, Båvenholm P, Hamsten A, (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92: 1851-1855.
4. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, et al. (2006) Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 367: 651-658.
5. Isordia-Salas I, Leaños-Miranda A, Sainz IM, Reyes-Maldonado E, Borrayo-Sánchez G, (2009) Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients. Rev Esp Cardiol 62: 365-372.
6. Abboud N, Ghazouani L, Saidi S, Ben-Hadj-Khalifa S, Addad F, et al. (2010) Association of PAI-1 4G/5G and-844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study. Genet Test Mol Biomarkers 14: 23-27.
7. Rallidis LS, Gialeraki A, Merkouri E, Liakos G, Dagres N, et al. (2010) Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction. J Thromb Thrombolysis 29: 497-502.
8. Ashavaid TF, Todur SP, Kondkar AA, Nair KG, Shalia KK, et al. (2011) Platelet polymorphisms: frequency distribution and association with coronary artery disease in an Indian population. Platelets 22: 85-91.
9. Dai Y, Gao RL, Ye Y, Wu YJ, Chen JL, et al. (2001) The 4G/5G genetic polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene is not associated with plasma PAI-1 antigen level and the risk of coronary artery disease in Chinese. Chinese Circulation Journal 16: 275-278.
10. Li XS, Xian SX, Huang HQ, (2002) Relationship between plasminogen activator inhibitor-1 gene and coronary heart diseasewith blood-stagnation syndrome. Journal of Guangzhou University of Traditional Chinese Medicine 19: 261-264.
11. Fu Y, Wang XD, Zhai YL, Fan Z, Yang L, et al. (2001) The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene in patients with coronary heart disease. Journal of Capital University of Medical Sciences 22: 119-122.
12. Guan L, Ji X, Wang J, Zhang A, Zhang Y, et al. (2002) Association of plasminogen activator inhibitor-1 gene 4G/5G polymorphism and coronary heart disease in Chinese patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19: 393-396.
13. Wang YS, Wang SY, Zhang M, Bai CX, Li SQ, (2003) Polymorphisms of PAI-1 4G/5G in patients with coronary heart disease complicated with or without OSAHS. New Medicine 34: 674-676.
14. Yin SQ, Liu S, Shun GY, Kan YD, Xie HQ, (2003) Correlation between plasminogen activator inhibitor-1 and its gene polymorphism and acute myocardial infarction. Tianjin Med J 31: 131-133.
15. Xia DS, Cao J, Song YQ, Hu SY, Guo QY, et al. (2006) Association between serotonin transporter and plasminogen activator inhibitor-1 gene polymorphisms and depressive disorder in patients with coronary heart disease. Chin J of Behavioral Med Sci 15: 481-483.
16. Zhan M, Zhou Y, Han Z, (2003) Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin Med J (Engl) 116: 1707-1710.
17. Cochran WG, (1968) The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 24: 295-313.
18. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
19. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
20. Egger M, Davey Smith G, Schneider M, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315: 629-634.
21. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, et al. (2002) Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 17: 56-61.
22. Franco RF, Reitsma PH, (2001) Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. Br J Haematol 115: 491-506.
23. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, et al. (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268: 10739-10745.
24. Eriksson P, Kallin B, Van't Hooft FM, Båvenholm P, Hamsten A, (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92: 1851-1855.
25. Böttiger C, Koch W, Lahn C, Mehilli J, Von Beckerath N, et al. (2003) 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J 146: 855-861.
26. Sampaio MF, Hirata MH, Hirata RD, Antos FC, Picciotti R, et al. (2007) AMI is associated with polymorphisms in the NOS3 and FGB but not in PAI-1 genes in young adults. Clin Chim Acta 377: 154-162.
27. Juhan-Vague I, Morange PE, Frere C, Aillaud MF, Alessi MC, et al. (2003) The plasminogen activator inhibitor-1-675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost 1: 2322-2329.
28. Onalan O, Balta G, Oto A, Kabakci G, Tokgozoglu L, et al. (2008) Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease. J Thromb Thrombolysis 26: 211-217.
29. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S, (1991) Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11: 183-190.
30. Iwai N, Shimoike H, Nakamura Y, Tamaki S, Kinoshita M, (1998) The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 136: 109-114.